ACRS
Aclaris Therapeutics, Inc. NASDAQ Listed Oct 6, 2015$4.86
Mkt Cap $586.1M
52w Low $1.16
99.2% of range
52w High $4.89
50d MA $3.83
200d MA $2.82
P/E (TTM)
-8.3x
EV/EBITDA
-5.5x
P/B
5.2x
Debt/Equity
0.0x
ROE
-63.0%
P/FCF
-7.8x
RSI (14)
—
ATR (14)
—
Beta
0.68
50d MA
$3.83
200d MA
$2.82
Avg Volume
1.8M
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
640 Lee Road · Wayne, PA 19087 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 4.78 | -2.3% | +1.7% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.15 | -0.16 | -6.7% | 3.13 | -1.6% | -8.3% | +6.3% | -0.3% | +2.0% | +0.6% | — |
| Nov 6, 2025 | AMC | -0.13 | -0.12 | +7.7% | 2.27 | -0.4% | +2.2% | -8.2% | +8.0% | +4.8% | -3.7% | — |
| Aug 7, 2025 | AMC | -0.13 | -0.13 | +0.0% | 1.57 | +0.0% | +3.8% | +0.6% | +0.0% | +3.7% | -0.6% | — |
| May 8, 2025 | AMC | -0.17 | -0.12 | +29.4% | 1.31 | -3.8% | -3.8% | -0.8% | -2.4% | -3.3% | +3.4% | — |
| Feb 27, 2025 | AMC | -0.09 | -0.10 | -11.1% | 1.95 | -2.6% | +2.1% | -1.5% | -1.5% | -4.1% | -1.6% | — |
| Nov 6, 2024 | AMC | -0.08 | -0.11 | -37.5% | 2.26 | +0.4% | +8.4% | +7.8% | -0.4% | -2.7% | -4.7% | — |
| Aug 7, 2024 | AMC | -0.19 | -0.15 | +21.1% | 1.19 | +0.8% | -1.7% | -0.9% | -1.7% | +4.4% | -1.7% | — |
| May 7, 2024 | AMC | -0.28 | -0.24 | +14.3% | 1.34 | -6.7% | -9.0% | +0.8% | -4.9% | +0.9% | +0.0% | — |
| Feb 27, 2024 | AMC | -0.37 | -0.30 | +18.9% | 1.20 | +0.0% | -0.8% | +0.0% | +4.2% | +0.8% | +1.6% | — |
| Nov 6, 2023 | AMC | -0.48 | -0.41 | +14.6% | 5.48 | +0.0% | -1.1% | +0.6% | -9.7% | -3.4% | -86.4% | — |
| Aug 7, 2023 | AMC | -0.45 | -0.42 | +6.7% | 9.14 | -0.3% | -5.3% | -2.1% | -1.7% | -1.4% | -3.2% | — |
| May 8, 2023 | AMC | -0.44 | -0.42 | +4.5% | 8.40 | -0.4% | -1.4% | +0.1% | -3.3% | -1.6% | +5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Guggenheim | Initiates | Buy | $12 | $4.53 | $4.72 | +4.2% | +4.9% | +0.6% | +1.7% | +1.4% | — |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $3.49 | $3.52 | +0.9% | +7.4% | +10.4% | +1.4% | -9.5% | -1.3% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.66 | $3.61 | -1.4% | +2.2% | -1.3% | -3.0% | -7.8% | +8.8% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.87 | $3.90 | +0.8% | -9.3% | -2.3% | +2.3% | +2.8% | -3.9% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.43 | $4.24 | -4.3% | -0.2% | +2.5% | -0.7% | -15.1% | +1.3% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.97 | +3.7% | +5.8% | +18.4% | -5.0% | +0.0% | -4.9% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.56 | +2.6% | +7.2% | -4.3% | -5.8% | -3.4% | -0.7% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.22 | $1.22 | +0.0% | -3.3% | +3.4% | +7.4% | -0.8% | +3.8% |
| May 9 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.31 | $1.26 | -3.8% | -3.8% | -0.8% | -2.4% | -3.3% | +3.4% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.58 | $1.59 | +0.6% | +0.0% | -1.9% | +1.3% | +1.9% | +6.2% |
| Dec 23 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.72 | $2.99 | +9.9% | +6.2% | +0.3% | +0.7% | -6.5% | -9.2% |
| Nov 19 | Jefferies | Upgrade | Hold → Buy | — | $3.14 | $3.71 | +18.2% | +46.2% | -13.7% | +9.1% | -12.0% | +5.0% |
| Nov 19 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $3.14 | $3.71 | +18.2% | +46.2% | -13.7% | +9.1% | -12.0% | +5.0% |
| Nov 19 | BTIG | Upgrade | Neutral → Buy | — | $3.14 | $3.71 | +18.2% | +46.2% | -13.7% | +9.1% | -12.0% | +5.0% |
| Nov 18 | Piper Sandler | Upgrade | Neutral → Overweight | — | $2.05 | $2.43 | +18.5% | +53.2% | +46.2% | -13.7% | +9.1% | -12.0% |
| Jan 22 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.14 | $1.19 | +4.4% | +10.5% | +1.6% | -1.6% | -0.8% | -1.6% |
| Jan 11 | BTIG | Downgrade | Buy → Neutral | — | $1.00 | $0.97 | -3.0% | -4.3% | -3.4% | +25.5% | +1.7% | +0.0% |
| Dec 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.07 | $1.09 | +1.9% | -1.9% | +0.0% | +6.7% | -1.8% | -3.6% |
| Dec 18 | Stifel | Maintains | Hold → Hold | — | $1.01 | $1.02 | +1.0% | -7.2% | +8.8% | -8.3% | +8.0% | +5.9% |
| Nov 14 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $0.64 | $0.67 | +4.3% | +5.5% | +17.9% | +10.4% | +7.8% | -1.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.64 | $0.67 | +4.3% | +5.5% | +17.9% | +10.4% | +7.8% | -1.5% |
| Nov 13 | William Blair | Downgrade | Outperform → Market Perform | — | $4.75 | $0.70 | -85.3% | -86.4% | +5.5% | +17.9% | +10.4% | +7.8% |
| Nov 13 | Stifel | Downgrade | Buy → Hold | — | $4.75 | $0.70 | -85.3% | -86.4% | +5.5% | +17.9% | +10.4% | +7.8% |
| Oct 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.06 | $6.05 | -0.2% | -5.0% | +4.7% | -2.2% | -6.1% | -4.0% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.26 | $6.20 | -1.0% | -3.8% | -1.7% | +2.4% | -5.0% | +4.7% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.43 | $7.42 | -0.1% | -0.4% | -8.5% | +0.7% | -2.5% | -1.4% |
| Sep 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.43 | $7.42 | -0.1% | -0.4% | -8.5% | +0.7% | -2.5% | -1.4% |
| Sep 14 | Stifel | Maintains | Buy → Buy | — | $7.58 | $7.94 | +4.7% | +5.5% | -5.6% | -1.6% | -0.4% | -8.5% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.14 | $9.11 | -0.3% | -5.3% | -2.1% | -1.7% | -1.4% | -3.2% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.46 | $9.50 | +0.4% | +0.7% | +4.0% | +3.1% | +3.9% | +0.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.07 | $7.07 | +0.0% | +4.8% | +6.3% | -2.8% | +3.0% | +4.7% |
| Mar 7 | BTIG | Maintains | Buy → Buy | — | $7.07 | $7.07 | +0.0% | +4.8% | +6.3% | -2.8% | +3.0% | +4.7% |
| Mar 7 | Goldman Sachs | Maintains | Buy → Buy | — | $7.07 | $7.07 | +0.0% | +4.8% | +6.3% | -2.8% | +3.0% | +4.7% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.77 | $12.53 | -1.9% | -5.5% | +0.4% | +2.8% | -1.8% | +3.1% |
| Feb 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.73 | $13.91 | +1.3% | +2.5% | -2.6% | +1.0% | +3.1% | -5.3% |
| Dec 14 | Stifel | Maintains | Buy → Buy | — | $15.94 | $16.33 | +2.4% | +1.4% | -3.2% | -0.4% | -6.4% | +3.0% |
| Dec 1 | Goldman Sachs | Maintains | Buy → Buy | — | $15.22 | $15.46 | +1.6% | +4.2% | +4.9% | -5.9% | +1.7% | -4.6% |
| Oct 6 | BTIG | Maintains | Buy → Buy | — | $15.75 | $16.41 | +4.2% | +6.0% | -5.3% | -2.1% | -2.1% | +1.7% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.81 | $18.32 | +2.9% | +1.0% | +0.9% | +0.7% | -2.1% | +0.4% |
| Jun 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.83 | $18.50 | +3.8% | -0.1% | +1.0% | +0.9% | +0.7% | -2.1% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.46 | $27.15 | +2.6% | +2.8% | -1.6% | -0.2% | -2.4% | -5.5% |
| Mar 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $21.98 | $21.76 | -1.0% | -3.8% | +0.8% | -0.3% | +5.8% | +1.6% |
| Jan 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $18.83 | $19.95 | +5.9% | -4.6% | +0.4% | +1.0% | -3.2% | -0.9% |
| Oct 23 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $1.61 | $1.62 | +0.6% | +2.5% | +1.8% | +6.0% | -6.7% | +14.5% |
| Oct 22 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $1.41 | $1.56 | +10.6% | +14.2% | +2.5% | +1.8% | +6.0% | -6.7% |
| Sep 6 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $0.92 | $0.88 | -4.5% | +9.7% | +3.0% | +7.7% | -0.9% | -2.7% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.99 | $0.95 | -4.0% | -9.1% | -5.7% | -2.5% | -5.1% | +1.8% |
| Jun 27 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $4.45 | $2.88 | -35.3% | -52.1% | +2.8% | +11.0% | -3.7% | +5.6% |
| May 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.34 | $6.28 | -0.9% | +4.1% | +1.2% | -1.6% | -9.7% | +1.0% |
| Oct 16 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $13.41 | $13.25 | -1.2% | -7.1% | -2.3% | +0.0% | +2.7% | +0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Leonard Braden Michael | — | Sell | 300,000 | $4.53 | $1.4M | 13,950,000 | -4.31% | +2.72% |
8-K · 2.02
!! High
Aclaris Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aclaris Therapeutics reported financial results and operational performance in a press release filed as an exhibit to its 8-K disclosure.
May 7
8-K · 8.01
!! High
Aclaris Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Aclaris Therapeutics announced positive ATI-2138 trial results for its ATI-052 candidate, potentially advancing the company's clinical pipeline and supporting future regulatory submissions.
Apr 28
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ACRS disclosed emerging growth company status via Regulation FD, potentially signaling lower compliance burdens and reduced disclosure requirements that may attract growth-focused investors but warrant scrutiny of financial reporting depth.
Mar 11
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ACRS disclosed emerging growth company status via Regulation FD, potentially signaling access to reduced disclosure requirements and regulatory relief that could lower compliance costs and improve near-term profitability.
Mar 10
8-K
Aclaris Therapeutics, Inc. -- 8-K Filing
Aclaris Therapeutics reported 2025 fourth-quarter and full-year financial results while maintaining its focus on immuno-inflammatory disease treatments, with CEO Neal Walker providing strategic corporate updates to investors.
Feb 26
Data updated apr 24, 2026 10:42am
· Source: massive.com